MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
29 November 2022 - 06:00PM
Business Wire
- MaaT Pharma will host a webcast conference for the investment
community in conjunction with the American Society of Haematology
Annual Meeting on December 12, 2022
- Hervé Affagard, CEO and key opinion leaders will discuss
clinical data presented at the conference, including extended
results for Microbiome Ecosystem TherapyTM (MET) MaaT013 in 81
patients with gastrointestinal acute Graft-vs-Host-Disease (GI
aGvHD) enrolled in Early Access Program and detailed results from
Phase 1b trial evaluating oral MET MaaT033 in patients with acute
myeloid leukemia
- The Company will also provide a corporate update during the
webcast
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
survival outcomes for patients with cancer, today announced
that it will host an investor webcast on Monday, December 12th,
2022 at 12:00 pm EST / 6:00 pm CET to comment on clinical data
scheduled to be presented at the 64th American Society of
Hematology (ASH) Annual Meeting and provide a corporate update for
shareholders and the broader financial community.
The webcast will feature clinical data presented in an oral
format on December 10th at the conference with the Company’s lead
candidate MaaT013 as salvage therapy in 81 patients with
treatment-resistant gastrointestinal acute Graft-vs-host-Disease
(GI aGvHD) enrolled in an Early Access Program (EAP) in France and
a poster presentation detailing results from the Phase 1b clinical
trial evaluating MaaT033 in patients with acute myeloid
leukemia.
Webcast details:
Date/Time: Monday, December 12, 2022; 6:00 pm CET
(expected to be approximately one hour in duration).
Registration: To register for the live webcast, please
click here.
Speakers:
- Hervé Affagard, CEO & co-founder of MaaT Pharma
- Prof. Mohamad Mohty, Professor and head of the
Hematology and Cellular Therapy Department at the Saint-Antoine
Hospital (AP-HP) and Sorbonne University,
- Prof. Florent Malard, Professor of Hematology, Saint
Antoine Hospital (AP-HP) and Associate Professor, Sorbonne
University
- Dr. Emilie Plantamura, Head of clinical development at
MaaT Pharma
The webcast will be held in English, with French subtitles. A
live Q&A session will be available in French and English.
Replay: A replay will be made available on the Company’s
website for at least 90 days.
About MaaT013
MaaT013 is a standardized, high-richness, high-diversity
Microbiome Ecosystem TherapyTM containing ButycoreTM (group of
bacterial genera known to produce immuno-regulatory metabolites).
It aims to restore the symbiotic relationship between the patient’s
functional gut microbiome and their immune system to correct the
responsiveness and tolerance of immune functions and reduce
steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has
been granted Orphan Drug Designation by the US Food and Drug
Administration (FDA) and the European Medicines Agency (EMA).
MaaT013 is an off-the-shelf, healthy-multi-donors-derived product
intended for acute, hospital use.
About MaaT033
MaaT033 is a standardized, high richness, oral Microbiome
Ecosystem TherapyTM. It aims to restore the gut ecosystem to full
functionality to improve clinical outcomes as well as to control
adverse events related to conventional treatments for liquid
tumors. The capsule formulation facilitates administration and
allows the potential to treat larger patients’ populations while
maintaining the high and consistent richness and diversity of
microbial species, including anti-inflammatory ButycoreTM species.
MaaT033 is an off-the-shelf, healthy-multi donors-derived oral
product intended for ambulatory setting.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022 in Europe, a Phase 3 clinical trial for patients with
acute GvHD, following the achievement of its proof of concept in a
Phase 2 trial. Its powerful discovery and analysis platform,
gutPrint®, supports the development and expansion of its pipeline
by determining novel disease targets, evaluating drug candidates,
and identifying biomarkers for microbiome-related conditions. The
company’s Microbiome Ecosystem Therapies are produced through a
standardized cGMP manufacturing and quality control process to
safely deliver the full diversity of the microbiome, in liquid and
oral formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is the first company
developing microbiome-based therapies listed on Euronext Paris
(ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221129005847/en/
MaaT Pharma – Investor relations Hervé AFFAGARD
Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00
invest@maat-pharma.com
MaaT Pharma - media relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 07 55 25 36
prichaud@maat-pharma.com
Trophic Communications - Corporate and medical
Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 151
7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Feb 2023 bis Mär 2023
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Mär 2022 bis Mär 2023
